What are the key steps to a successful pitch to healthcare agencies?

In the healthcare sector, a meeting with the regulatory authorities is never merely an administrative formality. Above all, it is a strategic step that requires rigorous project management. The quality of this dialogue has a direct impact on the development process of a new medicine. Whether you are dealing with the EMA for a European procedure or the ANSM in France (or any other regulatory agency) within a national framework, delivering a successful presentation to these experts is crucial for obtaining future Marketing Authorisation (MA). Alhena Consult, an expert in consultancy and operational support services, supports companies by ensuring the smooth running of every stage of this complex process, from early development through to post-approval activities.

 

 

The challenges of presenting to health authorities

A successful scientific presentation to the authorities is a major investment for a pharmaceutical group or a start-up. These meetings provide an opportunity to compare the scientific vision with the evaluators’ expectations, before development costs become prohibitive. The role of agencies such as the EMA or the ANSM is therefore to ensure patient safety whilst promoting medical innovation.

There are various types of regulatory meetings in Europe, ranging from Scientific Advice to pre-submission meetings. These discussions may also cover the Paediatric Investigation Plan (PIP) or the process of obtaining Orphan Drug Designation.

When it comes to cutting-edge therapies, it is useful to keep a close eye on approval timelines so that the overall market launch strategy can be adapted accordingly. Each meeting should therefore be seen as an opportunity to build a relationship of trust with the authorities.

 

 

Understanding the expectations of the regulatory agencies: EMA and ANSM

To succeed in this task, it is essential to adapt to the specific characteristics of each audience. Both the EMA and the ANSM have clear objectives: to validate the relevance of pharmaceutical, preclinical and clinical data and to ensure that the risk-benefit balance is favourable to the patient. The formats required are, therefore, strictly codified and must be based on scientific documentation of the highest quality.

Clarity and transparency are key when preparing technical documents and presentation slides. An effective presentation should not just look good. Above all, it must serve as factual evidence. Experts therefore expect complete consistency between the data presented in each visual and the substantive dossier already submitted. Any inconsistency can become a major sticking point and delay the product’s planned marketing process by several months. This rigour in presentation ensures a robust procedure for obtaining a Marketing Authorisation (MA).

 

 

The key steps to a successful presentation

Preparing and planning the presentation

Preparation is the first step towards success. It is essential to plan ahead for the meeting. To do this, drawing up a detailed reverse schedule helps to gather the relevant data, as well as to identify the most suitable in-house experts to contribute. This collaborative phase should result in the development of a clear message, in which every chart and every idea serves to support the main argument.

 

Team preparation and mastering the audition

Preparing the team is the second key step. It is not enough simply to have the data; you must also be able to present it confidently and manage the stress inherent in this type of hearing. Organising rehearsals that simulate the actual hearing helps to refine the language used and ensures that everyone in the group knows their role. A well-structured and consistent Q&A training session helps to answer the authorities’ most technical questions without hesitation.

 

D-Day session and strategic follow-up phase

On the day of the oral presentation, time management and a professional demeanour are crucial. At this stage, it is important to be factual and concise, and to maintain eye contact with the agency members to hold their attention. Finally, the follow-up after the presentation is all too often overlooked. However, it is essential to write a detailed report after the meeting. This is to analyse the agency’s feedback and adjust the development plan accordingly. This adjustment phase is critical, as it determines the project’s long-term viability. Regardless of the laboratory’s objective (national or European marketing), this stage finally confirms the prerequisites required to market a medicinal product in France and/or Europe.

A successful presentation does not end when the presentation is over. Follow-up is the stage that turns a verbal exchange into concrete regulatory decisions.

 

 

Mistakes to avoid when securing your project

One of the most common mistakes is to approach the agency with an unclear message or without having reached an internal consensus beforehand. If the company’s own experts cannot agree on the interpretation of a clinical result, the health authority will spot this immediately. This will seriously undermine its credibility. Similarly, providing unverified or incomplete data poses a significant risk and may slow down the consultation process with the agency and, ultimately, the approval of the medicinal product.

Underestimating the importance of communication and presentation is another common mistake. Even excellent scientific expertise risks not being fully appreciated if it is poorly presented. It is also important to pay attention to logistical matters, such as meeting submission deadlines and preparing supporting documents. The selection of service providers is a further risk factor.
Choosing the right partners for preclinical and clinical development ensures an unbroken data chain.

Finally, for drug candidates in the final stages of development, planning for post-marketing pharmacovigilance obligations in Europe must be considered from the dossier submission stage onwards.

 

 

The importance of expert support

Delivering a successful presentation to national or European agencies requires a thorough understanding of the subject matter and regulatory requirements. The company’s commitment to public health must be evident through flawless professional preparation. Seeking support from a regulatory affairs expert, such as Alhena Consult, is an invaluable service that can significantly improve your chances of success.

The impact of a favourable scientific opinion or a successful pre-submission is then measured in terms of time saved and faster market access. In addition to the approval of the main dossier, these meetings provide an opportunity to discuss specific schemes, such as early and compassionate access in France, in order to meet the needs of patients awaiting treatment. By managing every stage of the submission process effectively, the company is able to turn stringent regulatory constraints into genuine drivers of strategic development.

 

 

Sources

• ANSM (French National Agency for Medicines and Health Products Safety): framework for Scientific Advice and pre-submission meetings for the submission of Marketing Authorisation applications.
• EMA (European Medicines Agency): guidelines on interactions with the committees (CHMP/PRAC) under the Centralised Marketing Authorisation procedure.
• HAS (French National Authority for Health): guidelines on exceptional access schemes (early and compassionate access) in France.
• ICH (International Council for Harmonisation): international standards (M4) for the structure of technical and safety dossiers for healthcare products.